[Feature Stock] CMG Pharmaceutical falls on first day of trading after reverse stock split merger
Predicted impact: Low
Reverse split merger trading resumption; the trading halt was already reported in the last 14 days.
CMG PharmaceuticalCMG제약
058820 · KOSDAQ · ₩058820 · CMG제약
₩4,520▼ ₩460 (9.24%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −75.95%
- Market cap
- ₩67B
- Enterprise value
- ₩123B
- P/E
- 21.9×
- P/B
- 0.3×
- Dividend yield
- 0.0%
- ROE
- 1.5%
- Net margin
- 2.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−79.5% from the high
₩4,515Today: ₩4,515 – ₩4,980₩22,051
Returns
- 1W−19.6%
- 1M−17.4%
- 3M−35.0%
- 6M−74.9%
- YTD−75.7%
- 1Y−75.9%
- Volume today
- 177,687
- 2.3× the 20-day average
- Traded today
- ₩841M
- Listed shares
- 14,812,355
- EPS (12 months)
- ₩206
- Earnings yield 4.6%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−9.2% on Oct 28, 2026. Trading value 2.1× its normal.
CMG Pharmaceutical shares fell on their first day of trading after a reverse stock split and merger. The headline is the only information available, so the details of what happened remain unclear.
AI summary of the news and filings linked. It can be wrong; check them.
- • Foreign investors sold a net ₩297M that day
- • Buzz 76 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Buzzing- BuzzHighBuzz 76: heavy trading.
- SentimentNegativeNews: Shares fell on the first trading day after the reverse split and merger. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-18% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
CMG Pharmaceutical stock overview
CMG Pharmaceutical (CMG제약, KRX: 058820) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a pharmaceutical firm and a core affiliate of the Cha Bio Group, focused on researching, developing, manufacturing and selling medicines and health functional foods. Its shares closed at ₩4,520 on Oct 28, 2026, down 9.24% on the day, giving it a market value of ₩67B.
Key facts
- Market cap
- ₩67B
- Sector
- Biotech & Pharma
- Latest price change
- −9.24%
- As of
- Oct 28, 2026
- Main business
- The company is a pharmaceutical firm and a core affiliate of the Cha Bio Group, focused on researching, developing, manufacturing and selling medicines and health functional foods.
Quick answers about CMG Pharmaceutical
- What does CMG Pharmaceutical do?
- The company is a pharmaceutical firm and a core affiliate of the Cha Bio Group, focused on researching, developing, manufacturing and selling medicines and health functional foods. Its core technology, STARFILM, is an oral disintegrating film (ODF) platform, which it applies to improved new drugs. The company is expanding into growth areas such as anticancer drugs, anti-aging, ophthalmology, health functional foods and mom and baby products, and it also runs an animal medicine business through an affiliate.
- What is the market cap of CMG Pharmaceutical?
- The market capitalisation of CMG Pharmaceutical was ₩67B at the close on Oct 28, 2026.
- Who are the largest shareholders of CMG Pharmaceutical?
- According to the latest official filings, the largest reported holders are Cha Biotech (24.23%, as of Oct 12, 2026); Orion Asset Management (9.20%, as of Aug 7, 2026); Forward-NBH New Technology Business Investment Partnership No. 1 (4.18%, as of Jun 9, 2025).
- When is the next earnings report from CMG Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when CMG Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own CMG Pharmaceutical?
- Yes. The National Pension Service held 0.03% of CMG Pharmaceutical shares as of Dec 31, 2022.
Company profile
The company is a pharmaceutical firm and a core affiliate of the Cha Bio Group, focused on researching, developing, manufacturing and selling medicines and health functional foods. Its core technology, STARFILM, is an oral disintegrating film (ODF) platform, which it applies to improved new drugs. The company is expanding into growth areas such as anticancer drugs, anti-aging, ophthalmology, health functional foods and mom and baby products, and it also runs an animal medicine business through an affiliate.
Written by AI from the company's latest annual report.
- Korean name
- CMG제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 이주형
- Founded
- Aug 2001
- Listed
- Aug 2001
- Listed shares
- 14,812,355
- Fiscal year ends
- Month 12
- Website
- www.cmgpharma.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
CMG Pharmaceutical jointly develops pet nutritional supplement with SKY Animal Medical Center
Predicted impact: Low
Small joint pet supplement development with no financial size given.
Recent filings
See all- Trading haltOct 26, 2026
- 5%+ holding reportOct 14, 2026
- Early Redemption of Convertible Bonds (Including Overseas Convertible Bonds) Prior to Maturity (8th Series)Oct 12, 2026
- Insider shareholding reportOct 12, 2026
- 5%+ holding reportOct 12, 2026
Titles in Korean until English translations are added.
Also known as: CMG Pharmaceutical / CMG제약 / 058820 / KRX:058820
Source: KRX statistical information